ICH E6 regulatory guidelines have driven significant change to clinical trial monitoring and sponsor oversight in the past few years. In turn, these new guidelines have been the impetus for new innovations in process and technology, bringing increased operational efficiency, risk management, and higher quality oversight to clinical trials.

Artificial intelligence (AI) is a key driver of change in the clinical trial industry enabling alignment with the new regulatory guidelines. More specifically, generative AI and Chat GPT are the new buzzwords that have garnered a tremendous amount of recent attention. This discussion will focus on the potential of generative AI to change, improve, and disrupt current approaches to monitoring and sponsor oversight of clinical trials.

Join us to learn about how IQVIA’s Clinical Data Analytics Solutions (CDAS) is introducing conversational AI to analytics and transforming the approach to clinical trial oversight.

• Review and understand ICH E6 guidelines for sponsor oversight
• Discover the potential for generative AI to transform oversight
• Experience generative AI in action with IQVIA’s Clinical Analytics solution

Speakers

Adrian Kizewski
Associate Director, Clinical Tech, IQVIA Technologies

Rathipriya Bhaskar
Sr Product Manager, Clinical Data Analytics, IQVIA Technologies